Taselisib, a selective inhibitor of PIK3CA, is highly effective on PIK3CA-mutated and HER2/neu amplified uterine serous carcinoma in vitro and in vivo
- Resource Type
- Article
- Source
- In
Gynecologic Oncology November 2014 135(2):312-317 - Subject
- Language
- ISSN
- 0090-8258